Jason Aryeh Acquires Shares in Orchestra BioMed Holdings, Inc.
Jason Aryeh purchased 42,553 shares of Orchestra BioMed on June 23, 2026.
Key Points
- Jason Aryeh bought 42,553 shares of Orchestra BioMed Holdings, Inc. (OBIO) on June 23, 2026.
- Shares of OBIO traded at $3.98 on Friday, with a market cap of about $233.5 million.
- Analysts maintain a positive outlook, with recent price targets ranging from $10 to $20.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jason Aryeh, an insider at Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO), bought 42,553 shares of the company on June 23, 2026. The transaction did not involve a pre-arranged trading plan and was reported as a direct acquisition.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
Jason Aryeh's recent purchase comes amid other insider activity. On June 23, 2026, Eric Fain also bought 17,327 shares. Meanwhile, on June 24, 2026, insiders including Chris Cleary, John Prosper Mack, Eric Fain, and David Pacitti sold shares totaling several thousand each, though these sales were not part of any planned trading arrangements.
Orchestra BioMed Holdings, Inc. Stock Down 24.8%
Shares of Orchestra BioMed Holdings, Inc. traded at $3.98 on Friday. The company has a market capitalization of approximately $233.5 million. Despite its negative earnings per share of -$0.95, the firm is positioned in the healthcare sector, particularly within biotechnology, and carries a beta of 0.5. The stock's 52-week range is between $2.20 and $5.42, with a 50-day moving average of $4.03 and a 200-day moving average of $3.99. Orchestra BioMed maintains a strong liquidity position with a current ratio of 7.03 and a quick ratio of 6.90, alongside a debt-to-equity ratio of 31.10.
$OBIO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have shown confidence in Orchestra BioMed's potential. On May 19, 2026, B. Riley Securities maintained its 'buy' rating with a $10 price target. Similarly, HC Wainwright & Co. reiterated a 'buy' rating with the same target on May 14, 2026. Barclays also maintained a 'buy' rating, setting a higher target of $13 on May 13, 2026. Overall, the consensus target price is approximately $12.17, with six analysts contributing to this outlook.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a biomedical firm based in New Hope, Pennsylvania. The company, led by CEO David P. Hochman, focuses on developing innovative medical therapies. Its key products include the Atrioventricular Interval Modulation for lowering blood pressure and the Virtue Sirolimus AngioInfusion Balloon for treating artery disease. With a workforce of 86 employees, Orchestra BioMed also collaborates with Medtronic and Terumo for various medical advancements.
Bottom Line
Jason Aryeh's purchase of Orchestra BioMed shares highlights ongoing insider interest at the company. With its strategic partnerships and innovative product pipeline, Orchestra BioMed remains a company to watch in the biotechnology sector. However, as with all 13F filings and insider transactions, these disclosures reflect past positions and may not indicate current holdings.
Get Orchestra BioMed Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.